CAMBRIDGE, Mass., October 26, 2022 – Cerberus Therapeutics, Inc., an early-stage biotechnology company focused on development of proprietary nanobody-based platforms to create novel immunotherapeutics, today announced the appointment of Michael L. Dougan, an Assistant Professor of Medicine at Massachusetts General Hospital and Harvard Medical School and the Director of the Immunotherapy Mucosal Toxicities Program at Massachusetts General Hospital, to its Scientific Advisory Board.
“Dr. Dougan is a leading expert on immune regulation in the gastrointestinal tract. His research focus of translating immune mechanisms into novel treatment for inflammatory diseases of the gut will provide invaluable insights for Cerberus, especially as the company further dives into autoimmune disease areas like Celiac disease.” said Novalia Pishesha, Ph.D., Chief Executive Officer and Co-Founder of Cerberus Therapeutics.
About Cerberus Therapeutics
Founded in 2021 by Novalia Pishesha, Ph.D., Prof. Hidde Ploegh, Ph.D. and Prof. Harvey Lodish, Ph.D., Cerberus Therapeutics’ nanobody-based technology comprises two distinct platforms: one that targets autoimmunity and one aimed at infectious disease. Leveraging the unique biochemical properties and excellent targeting capabilities of alpaca-derived nanobodies (variable domains of heavy chain-only antibodies), Cerberus’ technology has the potential to reset the immune system and have it rewire itself for therapeutic gain.
Cerberus Contact:
Xiaohong Sang
617-416-6228
xsang@cerberustx.com